Hospital
Bon Secours Mercy Health Emporia LLC
Bon Secours Mercy Health Emporia LLC was paid $8.45M by Medicaid between Jan 2020 and Dec 2024, across 132 billing codes. Its largest line is 99283, emergency room visit (moderate) — 36% of everything it billed.
33Billing provider infoBON SECOURS MERCY HEALTH EMPORIA LLC
EMPORIA, VA 23847
EMPORIA, VA 23847
33aNPI1104461276assigned 11/13/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.45M
24GClaims201,344
24DCodes billed132
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#53 of 80
Median peer was paid$14.69M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 31,770 | $1.14M | |
| 2021 | 39,636 | $1.49M | |
| 2022 | 44,070 | $1.82M | |
| 2023 | 46,365 | $2.02M | |
| 2024incomplete | 39,503 | $1.99M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 36% | 17,888 | 15,436 | $3.01M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 9,904 | 8,081 | $1.49M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.7% | 5,460 | 4,397 | $823K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.5% | 3,469 | 3,054 | $553K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.6% | 1,468 | 1,211 | $390K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.4% | 8,858 | 1,927 | $373K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 2,230 | 1,887 | $368K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.5% | 1,371 | 1,167 | $208K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 784 | 673 | $159K |
| 97161 | 1.4% | 1,082 | 965 | $121K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 1,865 | 1,062 | $92K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.0% | 2,314 | 1,636 | $86K |
120 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,867 | $83K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 229 | $60K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 432 | $56K |
| G0378 | Hospital observation service, per hour | <1% | 239 | $55K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,086 | $51K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 223 | $49K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,987 | $46K |
| 97014 | <1% | 1,638 | $37K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 4,158 | $34K |
| 80053 | Comprehensive metabolic panel | <1% | 10,510 | $32K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,710 | $30K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 66 | $23K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,560 | $19K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,027 | $18K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,177 | $13K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 560 | $13K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 797 | $12K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 135 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,897 | $12K |
| 97016 | <1% | 650 | $11K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 710 | $9K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,150 | $9K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 14 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,106 | $8K |
| 83880 | <1% | 1,238 | $7K | |
| 81001 | <1% | 6,654 | $6K | |
| 87040 | <1% | 1,214 | $6K | |
| 81025 | <1% | 3,072 | $6K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 418 | $6K |
| 82962 | <1% | 3,185 | $5K | |
| 87070 | <1% | 1,594 | $3K | |
| 83605 | <1% | 1,953 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 330 | $3K |
| 85610 | <1% | 2,862 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,552 | $3K |
| 84484 | <1% | 5,758 | $2K | |
| 96376 | <1% | 950 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,370 | $2K |
| 73030 | <1% | 108 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,620 | $2K |
| 73560 | <1% | 215 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 169 | $2K |
| 81003 | <1% | 1,339 | $2K | |
| 86756 | <1% | 69 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 392 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 438 | $1K |
| 83735 | <1% | 3,415 | $1K | |
| 93971 | <1% | 13 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,888 | $883.99 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 155 | $867.24 |
| 97012 | <1% | 32 | $863.01 | |
| 87430 | <1% | 281 | $843.41 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,825 | $835.56 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,673 | $808.03 |
| 87807 | <1% | 603 | $759.90 | |
| 80143 | <1% | 231 | $752.92 | |
| 80061 | Lipid panel | <1% | 58 | $658.95 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 51 | $584.98 |
| 73562 | <1% | 86 | $577.75 | |
| 73502 | <1% | 30 | $572.79 | |
| 80179 | <1% | 183 | $509.31 | |
| 83690 | <1% | 2,049 | $499.55 | |
| 82077 | <1% | 1,313 | $474.23 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 404 | $470.93 |
| 74018 | <1% | 101 | $445.31 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,190 | $415.73 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 16 | $362.82 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,359 | $321.93 |
| 87186 | <1% | 41 | $315.86 | |
| 73630 | <1% | 16 | $289.07 | |
| 84702 | <1% | 13 | $286.25 | |
| 90714 | <1% | 14 | $281.39 | |
| J3490 | Unclassified drugs | <1% | 1,566 | $280.30 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 49 | $261.82 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 284 | $259.20 |
| 85730 | <1% | 395 | $254.20 | |
| 73610 | <1% | 13 | $253.06 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 154 | $211.16 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 656 | $198.43 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 454 | $174.28 |
| 85379 | <1% | 57 | $156.51 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,045 | $141.49 |
| 80050 | General health panel | <1% | 15 | $130.31 |
| 80320 | <1% | 113 | $124.83 | |
| 85027 | <1% | 64 | $109.74 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 206 | $101.90 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 50 | $78.84 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 70 | $76.44 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 193 | $65.85 |
| 82150 | <1% | 42 | $34.98 | |
| 86901 | <1% | 43 | $25.67 | |
| 86900 | <1% | 43 | $15.55 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 346 | $9.44 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 79 | $6.40 |
| 82565 | <1% | 32 | $5.50 | |
| 86850 | <1% | 30 | $5.40 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 63 | $5.29 |
| 82550 | <1% | 33 | $5.20 | |
| 87077 | <1% | 15 | $4.53 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 180 | $3.66 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 42 | $3.16 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 20 | $1.96 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 118 | $0.24 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 75 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 89 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 14 | $0.00 |
| 82803 | 0% | 16 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 18 | $0.00 |
| 73600 | 0% | 12 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 14 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 18 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 76 | $0.00 |
| 73130 | 0% | 15 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 160 | $0.00 |
| 93017 | 0% | 15 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 113 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 13 | $0.00 |
| 84145 | 0% | 16 | $0.00 | |
| 87634 | 0% | 33 | $0.00 | |
| 36600 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.